Table 3.
All adverse events of grade 3 and above and peripheral neuropathies of grades 1 and 2 that were reported
| Adverse event(s) | During metronidazole treatment phase (days 1–60) |
After metronidazole treatment phase (days > 60) |
||||
|---|---|---|---|---|---|---|
| No. (%) of patients receiving metronidazole (n = 16) | No. (%) of patients receiving placebo (n = 17) | Relative risk (95% CI) | No. (%) of patients receiving metronidazole (n = 16) | No. (%) of patients receiving placebo (n = 17) | Relative risk (95% CI) | |
| Aspergilloma | 1 (6.3) | 0 | ||||
| Diarrhea | 1 (6.3) | 1 (5.9) | 1.1 (0.1–15.6) | |||
| Fracture | 0 | 1 (5.9) | 0 | |||
| Gastritis | 1 (6.3) | 0 | ||||
| Hemoptysis | 1 (6.3) | 0 | ||||
| Hepatitis/elevated transaminases | 1 (6.3) | 0 | 1 (6.3) | 0 | ||
| Hypercholesterolemia | 0 | 1 (5.9) | 0 | |||
| Hyperglycemia | 0 | 1 (5.9) | 0 | 1 (6.3) | 1 (5.9) | 1.1 (0.1–15.6) |
| Hyperuricemia | 3 (18.8) | 3 (17.6) | 1.1 (0.2–4.5) | 3 (18.8) | 2 (11.8) | 1.6 (0.3–8.3) |
| Hypokalemia | 1 (6.3) | 0 | ||||
| Myalgia(s) | 0 | 1 (5.9) | 0 | |||
| Nausea | 1 (6.3) | 0 | ||||
| Peripheral neuropathy | 8 (50.0) | 2 (11.8) | 4.3 (1.1–17.1) | |||
| Pneumothorax | 0 | 1 (5.9) | 0 | |||
| Rash | 0 | 1 (5.9) | 0 | |||
| Seizure | 2 (12.5) | 1 (5.9) | 2.1 (0.2–21.2) | 1 (6.3) | 0 | |